Medicare Add-On Payments For New Dialysis Drugs Limited To ‘Innovative’ Products
Executive Summary
Centers for Medicare and Medicaid Services narrows the types of drugs eligible for add-on payments in the Medicare end-stage renal program as it tries to balance efforts to promote innovation with controlling costs.
You may also be interested in...
Medicare Dialysis Bundle And New Drugs: Will Transitional Payments Work For Korsuva, Vadadustat?
Quick provider uptake will be key for upcoming new drugs covered by the Medicare end stage renal disease prospective payment system.
Medicare Bundled Payment Policies Could Cut Amgen’s Parsabiv Sales By 50%
Amgen ‘looks forward’ to working with CMS and Congress to shape Medicare reimbursement policies in a way that better ensures access.
US Reimbursement Briefs: Medicare Payments For New Drugs; 340B Rules; HHS' Best
Recent developments in US federal government regulation of prescription drug pricing and reimbursement.